{
  "docId": "019de076-196c-761d-9e89-76fa4be124a4",
  "docSlug": "761321556bcd07be36b31e43721539e5",
  "documentTitle": "AbCellera | Investor Presentation Deck | 16 slides",
  "authorId": "abcellera",
  "authorName": "AbCellera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 16,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "Includes a disclaimer note at the top regarding the context of the earnings call.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-196c-761d-9e89-76fa4be124a4/15",
  "deckHref": "/decks/019de076-196c-761d-9e89-76fa4be124a4",
  "deckJsonHref": "/decks/019de076-196c-761d-9e89-76fa4be124a4.json",
  "deckAnchorHref": "/decks/019de076-196c-761d-9e89-76fa4be124a4#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.071,
        "w": 0.885,
        "x": 0.087,
        "y": 0.167
      },
      "kind": "disclaimer",
      "text": "Note: This document contains a condensed summary of AbCellera's 2023-11-02 earnings call. It should be read in conjunction with, and in the context of, the contents of the call itself.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e10a8524-4eb5-457e-ac6c-ccf13a9fc188",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.486,
        "w": 0.652,
        "x": 0.32,
        "y": 0.306
      },
      "kind": "list",
      "text": "ABCL575 targets the OX40 ligand (OX40L) and has been designed as a potential best-in-class therapy for atopic dermatitis and other indications in autoimmunity and inflammation. ABCL575 was discovered as part of AbCellera's 2021 co-development collaboration with EQRx. AbCellera took ownership of the program in Q3 2023. ABCL575 has been designed with potency, PK, and developability to enable less-frequent dosing than benchmark molecules. ABCL635 is the first pipeline asset from the company's GPCR and Ion Channel platform. ABCL635 hits an undisclosed target with an indication in metabolic and endocrine disorders. Overall market estimated at over $2 billion in annual sales. AbCellera anticipates potential IND submissions for ABCL575 and ABCL635 in 2025. AbCellera anticipates additional development candidates from AbCellera-led programs to advance into late-stage preclinical and IND-enabling studies in 2024 and 2025.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a33d9e7-2f5d-4240-89f9-490294424891",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.117,
        "w": 0.276,
        "x": 0.087,
        "y": 0.306
      },
      "kind": "paragraph",
      "text": "AbCellera achieves a significant company milestone, advancing two assets, ABCL575 and ABCL635, from AbCellera-led programs into IND-enabling studies.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6eece9f-ec38-4f60-9e0e-1a611879faa8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.071,
        "w": 0.458,
        "x": 0.087,
        "y": 0.055
      },
      "kind": "title",
      "text": "EARNINGS CALL SUMMARY",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04305263-b57f-4de8-a688-4a575522329f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "bc68c4c4-bbf0-4936-b9bd-5becaf086d5d",
      "evidence": "The slide has a type labeled as 'executive_summary'.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 14,
      "beatId": "2691e957-90cf-4871-8e75-f5956c920718",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The final slides summarize and conclude the presentation",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}